ReviewLeukemia2012
Bisphosphonates as antimyeloma drugs.
Review in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Multiomic profiling of responses to clinical and novel bisphosphonates reveals extraskeletal effects on ageing related signatures.Signal transduction and targeted therapy · 2026Article
- New Cytotoxic Derivatives by the Phosphorylation and Phosphinoylation of Diethyl α-Amino-α-Aryl-Methylphosphonates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- New Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors.Drug design, development and therapy · 2021Review
- The Endosomal Recycling Pathway-At the Crossroads of the Cell.International journal of molecular sciences · 2020Review
- Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Article
- Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis.Bioscience reports · 2018Article
- Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1.Oncotarget · 2017Article
- A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma.International journal of clinical and experimental medicine · 2015Article
- A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.PloS one · 2015Article
- Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.Bioorganic & medicinal chemistry letters · 2013Article
- Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.Current oncology (Toronto, Ont.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with symptomatic multiple myeloma (MM), bisphosphonate (BP) treatment has been widely used to prevent bone loss and preserve skeletal health because of its proven effects on inhibiting osteoclast-mediated bone resorption. In addition to their effects on osteoclasts, it is becoming increasingly evident that BPs may have additional effects on the bone microenvironment and cells other than osteoclasts that may potentially inhibit the development and progression of MM. This review focuses on the pathophysiology of MM with an emphasis on the events that drive MM progression within the bone and the mechanisms by which BPs may inhibit specific processes. The underlying molecular mechanisms that drive the modulation of cellular fate and function and consequent physiological outcomes are described. Direct effects on myeloma cell growth and survival and the interactions between myeloma cells and the bone microenvironment are discussed. Clinical evidence of the antimyeloma effects of BPs is emerging and is also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.